Search results for "FDA update"


 
Results 1 - 10 of about 100 for "FDA update".

FDA issues draft guidance on blood glucose monitors | ACP Diabetes Monthly

The updated recommendations apply to industry and, when finalized, will update previous guidance issued in 2016.

Test strips recalled | ACP Diabetes Monthly

Twenty lots of Abbott's FreeStyle and FreeStyle Lite blood glucose test strips were recalled.

Glucagon recalled due to detaching needles | ACP Diabetes Monthly

Six batches of GlucaGen HypoKit (glucagon [rDNA origin] for injection) were recalled due to the possibility of needle detachment, the FDA recently announced.

Test strips recalled | ACP Diabetes Monthly

The SPOTCHEM II Basic PANEL-1 Reagent Test Strip and SPOTCHEM II Glucose Reagent Test Strip may report falsely low blood glucose levels.

FDA clears marketing of first interoperable insulin pump | ACP Diabetes Monthly

The pump can be used with various components of diabetes therapy systems, including automated insulin dosing systems, continuous glucose monitors, and blood glucose meters.

Follow-on insulin lispro approved | ACP Diabetes Monthly

The injection is approved to improve glucose control in patients ages three years and older with type 1 diabetes and in adult patients with type 2 diabetes.

Warning on risks of canagliflozin | ACP Diabetes Monthly

The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased bone mineral density.

Hemoglobin A1c test approved for diagnosis | ACP Diabetes Monthly

The FDA recently approved the first hemoglobin A1c (HbA1c) test specifically labeled for diagnosing diabetes.

Ertugliflozin approved as adjunct treatment for type 2 diabetes | ACP Diabetes Monthly

As an adjunct to diet and exercise, the drug was approved as monotherapy and for use in fixed-dose combinations with metformin or sitagliptin.

New contraindication for aliskiren-containing medications | ACP Diabetes Monthly

Aliskiren-containing medications are contraindicated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with diabetes.

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next